Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on ANPARIO PLC. We currently have 1 research reports from 1 professional analysts.
|01Dec16 07:00||RNS||Total Voting Rights|
|22Nov16 07:00||RNS||Employee Share Plan and Directors' Dealing|
|06Oct16 11:46||RNS||Holding(s) in Company|
|16Sep16 04:36||RNS||Director/PDMR Shareholding and Share Plan Limits|
|09Sep16 03:21||RNS||Total Voting Rights|
|04Aug16 03:33||RNS||Total Voting Rights|
|04Aug16 03:32||RNS||Block listing Interim Review|
Frequency of research reports
Research reports on
VSA Agri Monthly
30 Sep 16
VSA Agri Thought for the Month Back in June we highlighted some early signs of stabilisation in the global dairy market that we believed might start to feed through into UK dairy prices over the following months. Although farmer-processor contracted milk prices have not increased as fast as some farmers would like, they are increasing, UK spot prices (a very small proportion of the market) are currently being quoted at more than 30ppl and in the past few months a number of ‘B contracts’ (i.e. those dealing with excess milk from farmers) from processors have actually been set above their respective ‘A contracts’. These factors all point towards steadily increasing contracted prices for UK dairy farmers in the coming months. In this issue of the VSA Agri Monthly we take a more in depth look at the UK dairy sector and conclude that the outlook is now much brighter for those dairy farmers that have managed to survive an extremely difficult last two years and for those listed agricultural input businesses that supply them.
N+1 Singer - Morning Song 05-12-2016
05 Dec 16
RTHM is acquiring a profitable Canadian listed mobile specialist for equivalent of US$42.5m consideration in shares (88.235m). This helps adds to two growth vectors RTHM is targeting; (i) adds unique exclusive audience (10m unique) and (ii) Exclusive demand Yahoo and Facebook. The business has 15 premium and owned and operated apps which provide users with rewards for activity. The business is expected to deliver c$9m of EBITDA in FY18 including $2m of cost synergies. This equates to just 4.7x EV/EBITDA. This marks what we see the first step in RTHM activity to scale the business and deliver on margin potential (see our initiation notes). Our initial estimates for EPS revisions are very significant - for FY18 are 2.3 cents (currently 0.6) and for FY19 4.3 (currently 2.5). There is a call at 830 for investors and we will revise post this.
Panmure Morning Note 02-12-16
02 Dec 16
We expect CareTech to report FY results to September on 8th December. A positive trading update in October indicated that performance for the year was in line with market expectations therefore we are focusing on the outlook. We expect a confident statement since the end of 2016 showed positive trends across fee rates, expansion in places and occupancy. We believe CareTech is well positioned for further expansion, and remains at an attractive valuation. We retain our BUY and 380p price target.
30 Nov 16
Abzena (ABZA): Interim results indicate happy customers (BUY) | Horizonte Minerals* (HZM): Fund raise completed (CORP) | SacOil* (SAC): Half-year trading statement (CORP) | Revolution Bars (RBG): New openings (BUY) | Amino Technologies* (AMO): Multi operator FUSION roll out (CORP)
Stuttering Generics weighs further on weak sentiment
30 Nov 16
Hikma gave a lacklustre Q3 16 trading update (no numbers) and has lowered its FY 16 revenue guidance (at cc) to $2bn from the previous $2-2.1bn. This was primarily on account of the continued sluggishness of the Generics segment. The Branded segment is also faring below expectations, besides facing higher-than-anticipated currency headwinds. The only positive is the sustained outperformance of the Injectables segment.
N+1 Singer - Morning Song 06-12-2016
06 Dec 16
With FY16 volume and revenue already disclosed in the pre-close, the focus in today’s prelims is on PBT (£100.3m versus our £101m) and EPS (96.8p versus our 95.4p). No special dividend triggered this year (none forecast) and DPS is held at 46.8p (N1SE: 48.0p). On end markets, recent commentary is reiterated – the core business is growing, whilst consumer electronics will be subdued in the current year (competitive capacity from Solvay). On currency, there will be a material benefit in the current year (a little more than the £14m to £15m previously indicated), and a further tailwind next year if current rates are maintained (quantum TBC). There is also an investment of £10m today in a minority interest in Magma Global, Victrex’ oil and gas mega programme partner. Although the share price is now close to our TP of 1730p, we feel that there is enough in today’s announcement to retain a positive stance on medium term opportunities with strong cashflow and a special dividend potentially to look forward to in the current year.